HRP20192195T1 - Derivati 7-(morfolin-4-il)pirazol[1,5-a]pirimidina koji su korisni za liječenje imunoloških ili upalnih oboljenja ili karcinoma - Google Patents
Derivati 7-(morfolin-4-il)pirazol[1,5-a]pirimidina koji su korisni za liječenje imunoloških ili upalnih oboljenja ili karcinoma Download PDFInfo
- Publication number
- HRP20192195T1 HRP20192195T1 HRP20192195TT HRP20192195T HRP20192195T1 HR P20192195 T1 HRP20192195 T1 HR P20192195T1 HR P20192195T T HRP20192195T T HR P20192195TT HR P20192195 T HRP20192195 T HR P20192195T HR P20192195 T1 HRP20192195 T1 HR P20192195T1
- Authority
- HR
- Croatia
- Prior art keywords
- methyl
- morpholin
- pyrazolo
- pyrimidine
- indol
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims 2
- 201000011510 cancer Diseases 0.000 title claims 2
- 208000027866 inflammatory disease Diseases 0.000 title claims 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 title 1
- 208000026278 immune system disease Diseases 0.000 title 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 18
- LDIJKUBTLZTFRG-UHFFFAOYSA-N pyrazolo[1,5-a]pyrimidine Chemical compound N1=CC=CN2N=CC=C21 LDIJKUBTLZTFRG-UHFFFAOYSA-N 0.000 claims 14
- -1 4,4-difluoropiperidinyl Chemical group 0.000 claims 3
- 125000004193 piperazinyl group Chemical group 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- XSDVSYYMDJSIGG-UHFFFAOYSA-N 4-[2-[(4-tert-butylpiperazin-1-yl)methyl]-5-[2-(difluoromethyl)benzimidazol-1-yl]pyrazolo[1,5-a]pyrimidin-7-yl]morpholine Chemical compound FC(C1=NC2=C(N1C1=NC=3N(C(=C1)N1CCOCC1)N=C(C=3)CN1CCN(CC1)C(C)(C)C)C=CC=C2)F XSDVSYYMDJSIGG-UHFFFAOYSA-N 0.000 claims 2
- FWMGDUYDYWYHHU-UHFFFAOYSA-N C(C)(C)(C)N1CCN(CC1)CC1=NN2C(N=C(C=C2N2CCOCC2)C2=C3C=CNC3=CC=C2F)=C1 Chemical compound C(C)(C)(C)N1CCN(CC1)CC1=NN2C(N=C(C=C2N2CCOCC2)C2=C3C=CNC3=CC=C2F)=C1 FWMGDUYDYWYHHU-UHFFFAOYSA-N 0.000 claims 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- ZIOJSHZDBRHNPU-UHFFFAOYSA-N N1C=CC2=C(C=NC=C12)C1=NC=2N(C(=C1)N1CCOCC1)N=C(C=2)CN1CCN(CC1)C(C)(C)C Chemical compound N1C=CC2=C(C=NC=C12)C1=NC=2N(C(=C1)N1CCOCC1)N=C(C=2)CN1CCN(CC1)C(C)(C)C ZIOJSHZDBRHNPU-UHFFFAOYSA-N 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- HZJFGIMFTGGOIZ-UHFFFAOYSA-N (4-tert-butylpiperazin-1-yl)-[5-(1H-indol-4-yl)-7-morpholin-4-ylpyrazolo[1,5-a]pyrimidin-2-yl]methanone Chemical compound CC(C)(C)N1CCN(CC1)C(=O)C1=NN2C(=C1)N=C(C=C2N1CCOCC1)C1=C2C=CNC2=CC=C1 HZJFGIMFTGGOIZ-UHFFFAOYSA-N 0.000 claims 1
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims 1
- NDOVLWQBFFJETK-UHFFFAOYSA-N 1,4-thiazinane 1,1-dioxide Chemical group O=S1(=O)CCNCC1 NDOVLWQBFFJETK-UHFFFAOYSA-N 0.000 claims 1
- HNVIQLPOGUDBSU-UHFFFAOYSA-N 2,6-dimethylmorpholine Chemical group CC1CNCC(C)O1 HNVIQLPOGUDBSU-UHFFFAOYSA-N 0.000 claims 1
- OCACOXJRRUBXFY-UHFFFAOYSA-N 4-[2-[(4-tert-butylpiperazin-1-yl)methyl]-3-chloro-5-[2-(difluoromethyl)benzimidazol-1-yl]pyrazolo[1,5-a]pyrimidin-7-yl]morpholine Chemical compound CC(C)(C)N1CCN(CC2=NN3C(N=C(C=C3N3CCOCC3)N3C(=NC4=CC=CC=C34)C(F)F)=C2Cl)CC1 OCACOXJRRUBXFY-UHFFFAOYSA-N 0.000 claims 1
- KRCDWKMSXXERJP-UHFFFAOYSA-N 4-[2-[(4-tert-butylpiperazin-1-yl)methyl]-5-(2-methylbenzimidazol-1-yl)pyrazolo[1,5-a]pyrimidin-7-yl]morpholine Chemical compound CC1=NC2=C(N1C1=NC=3N(C(=C1)N1CCOCC1)N=C(C=3)CN1CCN(CC1)C(C)(C)C)C=CC=C2 KRCDWKMSXXERJP-UHFFFAOYSA-N 0.000 claims 1
- PEZCEJLFYLMAJN-UHFFFAOYSA-N 4-[3-bromo-2-[(4-tert-butylpiperazin-1-yl)methyl]-5-[2-(difluoromethyl)benzimidazol-1-yl]pyrazolo[1,5-a]pyrimidin-7-yl]morpholine Chemical compound CC(C)(C)N1CCN(CC2=NN3C(N=C(C=C3N3CCOCC3)N3C(=NC4=CC=CC=C34)C(F)F)=C2Br)CC1 PEZCEJLFYLMAJN-UHFFFAOYSA-N 0.000 claims 1
- ZLKKONAGYKLDGT-UHFFFAOYSA-N C(C)(C)(C)C1CCN(CC1)CC1=NN2C(N=C(C=C2N2CCOCC2)C2=C3C=CNC3=CC=C2)=C1 Chemical compound C(C)(C)(C)C1CCN(CC1)CC1=NN2C(N=C(C=C2N2CCOCC2)C2=C3C=CNC3=CC=C2)=C1 ZLKKONAGYKLDGT-UHFFFAOYSA-N 0.000 claims 1
- BRSHENDWVTYDIF-UHFFFAOYSA-N C(C)(C)(C)N1CCN(CC1)CC1=NN2C(N=C(C=C2N2CCOCC2)C2=C3C=CNC3=CC=C2)=C1 Chemical compound C(C)(C)(C)N1CCN(CC1)CC1=NN2C(N=C(C=C2N2CCOCC2)C2=C3C=CNC3=CC=C2)=C1 BRSHENDWVTYDIF-UHFFFAOYSA-N 0.000 claims 1
- VMGOQBKQBAEBTD-UHFFFAOYSA-N C(C)(C)(C)N1CCN(CC1)CC1=NN2C(N=C(C=C2N2CCOCC2)C2=C3C=CNC3=CC=C2)=C1C Chemical compound C(C)(C)(C)N1CCN(CC1)CC1=NN2C(N=C(C=C2N2CCOCC2)C2=C3C=CNC3=CC=C2)=C1C VMGOQBKQBAEBTD-UHFFFAOYSA-N 0.000 claims 1
- FRLVLNCXWPBXMR-UHFFFAOYSA-N C(C)(C)(C)N1CCN(CC1)CC1=NN2C(N=C(C=C2N2CCOCC2)C2=C3C=NNC3=CC=C2)=C1 Chemical compound C(C)(C)(C)N1CCN(CC1)CC1=NN2C(N=C(C=C2N2CCOCC2)C2=C3C=NNC3=CC=C2)=C1 FRLVLNCXWPBXMR-UHFFFAOYSA-N 0.000 claims 1
- WEWYVCWZVZMAJT-UHFFFAOYSA-N C(C)(C)C1=NC2=C(N1C1=NC=3N(C(=C1)N1CCOCC1)N=C(C=3)CN1CCC(CC1)C(C)(C)O)C=CC=C2 Chemical compound C(C)(C)C1=NC2=C(N1C1=NC=3N(C(=C1)N1CCOCC1)N=C(C=3)CN1CCC(CC1)C(C)(C)O)C=CC=C2 WEWYVCWZVZMAJT-UHFFFAOYSA-N 0.000 claims 1
- KIHRZLPYOGDVMD-UHFFFAOYSA-N C(C)(C)C1=NC2=C(N1C1=NC=3N(C(=C1)N1CCOCC1)N=C(C=3)CN1CCN(CC1)C(C)(C)C)C=CC=C2 Chemical compound C(C)(C)C1=NC2=C(N1C1=NC=3N(C(=C1)N1CCOCC1)N=C(C=3)CN1CCN(CC1)C(C)(C)C)C=CC=C2 KIHRZLPYOGDVMD-UHFFFAOYSA-N 0.000 claims 1
- KXQOZDOHLZFJOK-UHFFFAOYSA-N C(C)C1=NC2=C(N1C1=NC=3N(C(=C1)N1CCOCC1)N=C(C=3)CN1CCC(CC1)N1CCN(CC1)C)C=CC=C2 Chemical compound C(C)C1=NC2=C(N1C1=NC=3N(C(=C1)N1CCOCC1)N=C(C=3)CN1CCC(CC1)N1CCN(CC1)C)C=CC=C2 KXQOZDOHLZFJOK-UHFFFAOYSA-N 0.000 claims 1
- UDXIJLHBTYEFCG-UHFFFAOYSA-N C(C)C1=NC2=C(N1C1=NC=3N(C(=C1)N1CCOCC1)N=C(C=3)CN1CCN(CC1)C(C)(C)C)C=CC(=C2)OC Chemical compound C(C)C1=NC2=C(N1C1=NC=3N(C(=C1)N1CCOCC1)N=C(C=3)CN1CCN(CC1)C(C)(C)C)C=CC(=C2)OC UDXIJLHBTYEFCG-UHFFFAOYSA-N 0.000 claims 1
- YBBKAFXOPYRZDT-UHFFFAOYSA-N C(C)C1=NC2=C(N1C1=NC=3N(C(=C1)N1CCOCC1)N=C(C=3)CN1CCN(CC1)C(C)(C)C)C=CC=C2 Chemical compound C(C)C1=NC2=C(N1C1=NC=3N(C(=C1)N1CCOCC1)N=C(C=3)CN1CCN(CC1)C(C)(C)C)C=CC=C2 YBBKAFXOPYRZDT-UHFFFAOYSA-N 0.000 claims 1
- NEPJMAOWDJLUEO-UHFFFAOYSA-N C(C)C1=NC2=C(N1C1=NC=3N(C(=C1)N1CCOCC1)N=C(C=3)CN1CCN(CC1)C1=CC=C(C=C1)OC)C=CC=C2 Chemical compound C(C)C1=NC2=C(N1C1=NC=3N(C(=C1)N1CCOCC1)N=C(C=3)CN1CCN(CC1)C1=CC=C(C=C1)OC)C=CC=C2 NEPJMAOWDJLUEO-UHFFFAOYSA-N 0.000 claims 1
- QPLKNJBRUXOGQP-UHFFFAOYSA-N C(C)C1=NC2=C(N1C1=NC=3N(C(=C1)N1CCOCC1)N=C(C=3)CN1CCN(CC1)S(=O)(=O)C)C=CC=C2 Chemical compound C(C)C1=NC2=C(N1C1=NC=3N(C(=C1)N1CCOCC1)N=C(C=3)CN1CCN(CC1)S(=O)(=O)C)C=CC=C2 QPLKNJBRUXOGQP-UHFFFAOYSA-N 0.000 claims 1
- DXUQUXJEVBITPI-UHFFFAOYSA-N C(C)C=1N(C2=C(C=NC=C2)N=1)C1=NC=2N(C(=C1)N1CCOCC1)N=C(C=2)CN1CCN(CC1)C(C)(C)C Chemical compound C(C)C=1N(C2=C(C=NC=C2)N=1)C1=NC=2N(C(=C1)N1CCOCC1)N=C(C=2)CN1CCN(CC1)C(C)(C)C DXUQUXJEVBITPI-UHFFFAOYSA-N 0.000 claims 1
- MMRSTUPIMUGONR-UHFFFAOYSA-N C(C)N1CCN(CC1)CC1=NN2C(N=C(C=C2N2CCOCC2)C2=C3C=CNC3=CC=C2)=C1 Chemical compound C(C)N1CCN(CC1)CC1=NN2C(N=C(C=C2N2CCOCC2)C2=C3C=CNC3=CC=C2)=C1 MMRSTUPIMUGONR-UHFFFAOYSA-N 0.000 claims 1
- NJEYAZTXZIVLAA-UHFFFAOYSA-N C(C)NC(NC1CCN(CC1)CC1=NN2C(N=C(C=C2N2CCOCC2)C2=C3C=CNC3=CC=C2)=C1)=O Chemical compound C(C)NC(NC1CCN(CC1)CC1=NN2C(N=C(C=C2N2CCOCC2)C2=C3C=CNC3=CC=C2)=C1)=O NJEYAZTXZIVLAA-UHFFFAOYSA-N 0.000 claims 1
- HTKQROOPMOLEIN-UHFFFAOYSA-N C1(=CC=CC=C1)NC(=O)NC1CCN(CC1)CC1=NN2C(N=C(C=C2N2CCOCC2)C2=C3C=CNC3=CC=C2)=C1 Chemical compound C1(=CC=CC=C1)NC(=O)NC1CCN(CC1)CC1=NN2C(N=C(C=C2N2CCOCC2)C2=C3C=CNC3=CC=C2)=C1 HTKQROOPMOLEIN-UHFFFAOYSA-N 0.000 claims 1
- NDVWKVKVWRRMCD-UHFFFAOYSA-N C1(CC1)C1=NC2=C(N1C1=NC=3N(C(=C1)N1CCOCC1)N=C(C=3)CN1CCN(CC1)C(C)(C)C)C=CC=C2 Chemical compound C1(CC1)C1=NC2=C(N1C1=NC=3N(C(=C1)N1CCOCC1)N=C(C=3)CN1CCN(CC1)C(C)(C)C)C=CC=C2 NDVWKVKVWRRMCD-UHFFFAOYSA-N 0.000 claims 1
- MKLVWXHGKNDJGJ-UHFFFAOYSA-N C1(CC1)N1CCN(CC1)CC1=NN2C(N=C(C=C2N2CCOCC2)C2=C3C=CNC3=CC=C2)=C1 Chemical compound C1(CC1)N1CCN(CC1)CC1=NN2C(N=C(C=C2N2CCOCC2)C2=C3C=CNC3=CC=C2)=C1 MKLVWXHGKNDJGJ-UHFFFAOYSA-N 0.000 claims 1
- URNJZPIRSYNKIK-UHFFFAOYSA-N CC1=NC2=C(N1C1=NC=3N(C(=C1)N1CCOCC1)N=C(C=3)CN1CCC(CC1)C(C)(C)O)C=CC=C2 Chemical compound CC1=NC2=C(N1C1=NC=3N(C(=C1)N1CCOCC1)N=C(C=3)CN1CCC(CC1)C(C)(C)O)C=CC=C2 URNJZPIRSYNKIK-UHFFFAOYSA-N 0.000 claims 1
- PJIQBNIWRVDLRJ-UHFFFAOYSA-N CN(C1CCN(CC1)CC1=NN2C(N=C(C=C2N2CCOCC2)C2=C3C=CNC3=CC=C2)=C1)C Chemical compound CN(C1CCN(CC1)CC1=NN2C(N=C(C=C2N2CCOCC2)C2=C3C=CNC3=CC=C2)=C1)C PJIQBNIWRVDLRJ-UHFFFAOYSA-N 0.000 claims 1
- KRSAMBUUJKOYQC-UHFFFAOYSA-N CN(C1CCN(CC1)CC1=NN2C(N=C(C=C2N2CCOCC2)C2=C3C=CNC3=CC=C2F)=C1)C Chemical compound CN(C1CCN(CC1)CC1=NN2C(N=C(C=C2N2CCOCC2)C2=C3C=CNC3=CC=C2F)=C1)C KRSAMBUUJKOYQC-UHFFFAOYSA-N 0.000 claims 1
- SBDLKFDJBXAMHC-UHFFFAOYSA-N COCC1=NC2=C(N1C1=NC=3N(C(=C1)N1CCOCC1)N=C(C=3)CN1CCN(CC1)C(C)(C)C)C=CC=C2 Chemical compound COCC1=NC2=C(N1C1=NC=3N(C(=C1)N1CCOCC1)N=C(C=3)CN1CCN(CC1)C(C)(C)C)C=CC=C2 SBDLKFDJBXAMHC-UHFFFAOYSA-N 0.000 claims 1
- WUPBAPLHGBOSES-UHFFFAOYSA-N FC(C1=NC2=C(N1C1=NC=3N(C(=C1)N1CCOCC1)N=C(C=3)CN1CC(C1)N1CC(C1)OC)C=CC=C2)F Chemical compound FC(C1=NC2=C(N1C1=NC=3N(C(=C1)N1CCOCC1)N=C(C=3)CN1CC(C1)N1CC(C1)OC)C=CC=C2)F WUPBAPLHGBOSES-UHFFFAOYSA-N 0.000 claims 1
- MRESNRVAYNZEJD-UHFFFAOYSA-N FC(C1=NC2=C(N1C1=NC=3N(C(=C1)N1CCOCC1)N=C(C=3)CN1CC(C1)N1CCC(CC1)(F)F)C=CC=C2)F Chemical compound FC(C1=NC2=C(N1C1=NC=3N(C(=C1)N1CCOCC1)N=C(C=3)CN1CC(C1)N1CCC(CC1)(F)F)C=CC=C2)F MRESNRVAYNZEJD-UHFFFAOYSA-N 0.000 claims 1
- VZHWTFOSTGCGTD-UHFFFAOYSA-N FC(C1=NC2=C(N1C1=NC=3N(C(=C1)N1CCOCC1)N=C(C=3)CN1CC(C1)N1CCOCC1)C=CC=C2)F Chemical compound FC(C1=NC2=C(N1C1=NC=3N(C(=C1)N1CCOCC1)N=C(C=3)CN1CC(C1)N1CCOCC1)C=CC=C2)F VZHWTFOSTGCGTD-UHFFFAOYSA-N 0.000 claims 1
- RFOKAEXRLTUCEU-KDURUIRLSA-N FC(C1=NC2=C(N1C1=NC=3N(C(=C1)N1CCOCC1)N=C(C=3)CN1CC(C1)N1C[C@H](O[C@H](C1)C)C)C=CC=C2)F Chemical compound FC(C1=NC2=C(N1C1=NC=3N(C(=C1)N1CCOCC1)N=C(C=3)CN1CC(C1)N1C[C@H](O[C@H](C1)C)C)C=CC=C2)F RFOKAEXRLTUCEU-KDURUIRLSA-N 0.000 claims 1
- ZOPLNEVOBWUGDN-UHFFFAOYSA-N FC(C1=NC2=C(N1C1=NC=3N(C(=C1)N1CCOCC1)N=C(C=3)CN1CCC(CC1)C(C)(C)O)C=CC(=C2)OC)F Chemical compound FC(C1=NC2=C(N1C1=NC=3N(C(=C1)N1CCOCC1)N=C(C=3)CN1CCC(CC1)C(C)(C)O)C=CC(=C2)OC)F ZOPLNEVOBWUGDN-UHFFFAOYSA-N 0.000 claims 1
- UEZRMIDWCGIYJW-UHFFFAOYSA-N FC(C1=NC2=C(N1C1=NC=3N(C(=C1)N1CCOCC1)N=C(C=3)CN1CCN(CC1)C(C)(C)C)C=CC(=C2)OC)F Chemical compound FC(C1=NC2=C(N1C1=NC=3N(C(=C1)N1CCOCC1)N=C(C=3)CN1CCN(CC1)C(C)(C)C)C=CC(=C2)OC)F UEZRMIDWCGIYJW-UHFFFAOYSA-N 0.000 claims 1
- WPXCZUXVJAJRJM-UHFFFAOYSA-N FC(C1=NC2=C(N1C1=NC=3N(C(=C1)N1CCOCC1)N=C(C=3C)CN1CCC(CC1)C(C)(C)O)C=CC=C2)F Chemical compound FC(C1=NC2=C(N1C1=NC=3N(C(=C1)N1CCOCC1)N=C(C=3C)CN1CCC(CC1)C(C)(C)O)C=CC=C2)F WPXCZUXVJAJRJM-UHFFFAOYSA-N 0.000 claims 1
- PLJVPKHTJCPKJW-UHFFFAOYSA-N FC(C1=NC2=C(N1C1=NC=3N(C(=C1)N1CCOCC1)N=C(C=3C)CN1CCN(CC1)C(C)(C)C)C=CC=C2)F Chemical compound FC(C1=NC2=C(N1C1=NC=3N(C(=C1)N1CCOCC1)N=C(C=3C)CN1CCN(CC1)C(C)(C)C)C=CC=C2)F PLJVPKHTJCPKJW-UHFFFAOYSA-N 0.000 claims 1
- GYKQWWLZAJYZBX-UHFFFAOYSA-N FC(C=1N(C2=C(C=NC=C2)N=1)C1=NC=2N(C(=C1)N1CCOCC1)N=C(C=2)CN1CCN(CC1)C(C)(C)C)F Chemical compound FC(C=1N(C2=C(C=NC=C2)N=1)C1=NC=2N(C(=C1)N1CCOCC1)N=C(C=2)CN1CCN(CC1)C(C)(C)C)F GYKQWWLZAJYZBX-UHFFFAOYSA-N 0.000 claims 1
- TWIFLXPJHDRMAK-UHFFFAOYSA-N FC=1C(=C2C=CNC2=CC=1)C1=NC=2N(C(=C1)N1CCOCC1)N=C(C=2)CN1CCC(CC1)N1CCN(CC1)C Chemical compound FC=1C(=C2C=CNC2=CC=1)C1=NC=2N(C(=C1)N1CCOCC1)N=C(C=2)CN1CCC(CC1)N1CCN(CC1)C TWIFLXPJHDRMAK-UHFFFAOYSA-N 0.000 claims 1
- GQRQFPOINDEAQD-UHFFFAOYSA-N FC=1C(=C2C=CNC2=CC=1)C1=NC=2N(C(=C1)N1CCOCC1)N=C(C=2)CN1CCN(CC1)C(C(=O)N)(C)C Chemical compound FC=1C(=C2C=CNC2=CC=1)C1=NC=2N(C(=C1)N1CCOCC1)N=C(C=2)CN1CCN(CC1)C(C(=O)N)(C)C GQRQFPOINDEAQD-UHFFFAOYSA-N 0.000 claims 1
- YRYGQUNSYBUJCH-UHFFFAOYSA-N N1C=CC2=C(C=CC=C12)C1=NC=2N(C(=C1)N1CCOCC1)N=C(C=2)CN1CC(C1)N1CCOCC1 Chemical compound N1C=CC2=C(C=CC=C12)C1=NC=2N(C(=C1)N1CCOCC1)N=C(C=2)CN1CC(C1)N1CCOCC1 YRYGQUNSYBUJCH-UHFFFAOYSA-N 0.000 claims 1
- ZKQQJOKDKRUWCE-UHFFFAOYSA-N N1C=CC2=C(C=CC=C12)C1=NC=2N(C(=C1)N1CCOCC1)N=C(C=2)CN1CC(C1)N1CCS(CC1)(=O)=O Chemical compound N1C=CC2=C(C=CC=C12)C1=NC=2N(C(=C1)N1CCOCC1)N=C(C=2)CN1CC(C1)N1CCS(CC1)(=O)=O ZKQQJOKDKRUWCE-UHFFFAOYSA-N 0.000 claims 1
- LNSOHHCOIRLBFN-UHFFFAOYSA-N N1C=CC2=C(C=CC=C12)C1=NC=2N(C(=C1)N1CCOCC1)N=C(C=2)CN1CCC(CC1)C(=O)OC Chemical compound N1C=CC2=C(C=CC=C12)C1=NC=2N(C(=C1)N1CCOCC1)N=C(C=2)CN1CCC(CC1)C(=O)OC LNSOHHCOIRLBFN-UHFFFAOYSA-N 0.000 claims 1
- UZWLPUAGEVOOLV-UHFFFAOYSA-N N1C=CC2=C(C=CC=C12)C1=NC=2N(C(=C1)N1CCOCC1)N=C(C=2)CN1CCC(CC1)C1COC1 Chemical compound N1C=CC2=C(C=CC=C12)C1=NC=2N(C(=C1)N1CCOCC1)N=C(C=2)CN1CCC(CC1)C1COC1 UZWLPUAGEVOOLV-UHFFFAOYSA-N 0.000 claims 1
- VJNBWPAOLXJVEU-UHFFFAOYSA-N N1C=CC2=C(C=CC=C12)C1=NC=2N(C(=C1)N1CCOCC1)N=C(C=2)CN1CCC(CC1)N1CCN(CC1)C Chemical compound N1C=CC2=C(C=CC=C12)C1=NC=2N(C(=C1)N1CCOCC1)N=C(C=2)CN1CCC(CC1)N1CCN(CC1)C VJNBWPAOLXJVEU-UHFFFAOYSA-N 0.000 claims 1
- NAJXBJXXLWPFOV-UHFFFAOYSA-N N1C=CC2=C(C=CC=C12)C1=NC=2N(C(=C1)N1CCOCC1)N=C(C=2)CN1CCN(CC1)C(C(=O)N)(C)C Chemical compound N1C=CC2=C(C=CC=C12)C1=NC=2N(C(=C1)N1CCOCC1)N=C(C=2)CN1CCN(CC1)C(C(=O)N)(C)C NAJXBJXXLWPFOV-UHFFFAOYSA-N 0.000 claims 1
- VJGZRHOIIYPNGU-UHFFFAOYSA-N N1C=CC2=C(C=CC=C12)C1=NC=2N(C(=C1)N1CCOCC1)N=C(C=2)CN1CCN(CC1)C1=CC=C(C=C1)OC Chemical compound N1C=CC2=C(C=CC=C12)C1=NC=2N(C(=C1)N1CCOCC1)N=C(C=2)CN1CCN(CC1)C1=CC=C(C=C1)OC VJGZRHOIIYPNGU-UHFFFAOYSA-N 0.000 claims 1
- WIASMVUGZCWVSZ-UHFFFAOYSA-N N1C=CC2=C(C=CC=C12)C1=NC=2N(C(=C1)N1CCOCC1)N=C(C=2)CN1CCN(CC1)S(=O)(=O)C Chemical compound N1C=CC2=C(C=CC=C12)C1=NC=2N(C(=C1)N1CCOCC1)N=C(C=2)CN1CCN(CC1)S(=O)(=O)C WIASMVUGZCWVSZ-UHFFFAOYSA-N 0.000 claims 1
- JZHDJRGYWKCVGW-UHFFFAOYSA-N N1C=CC2=C(C=CN=C12)C1=NC=2N(C(=C1)N1CCOCC1)N=C(C=2)CN1CCC(CC1)C(C)(C)O Chemical compound N1C=CC2=C(C=CN=C12)C1=NC=2N(C(=C1)N1CCOCC1)N=C(C=2)CN1CCC(CC1)C(C)(C)O JZHDJRGYWKCVGW-UHFFFAOYSA-N 0.000 claims 1
- YVVIGCKZPAVDOD-UHFFFAOYSA-N N1C=CC2=C(C=CN=C12)C1=NC=2N(C(=C1)N1CCOCC1)N=C(C=2)CN1CCN(CC1)C(C)(C)C Chemical compound N1C=CC2=C(C=CN=C12)C1=NC=2N(C(=C1)N1CCOCC1)N=C(C=2)CN1CCN(CC1)C(C)(C)C YVVIGCKZPAVDOD-UHFFFAOYSA-N 0.000 claims 1
- SSQIVSBCTXQXDN-UHFFFAOYSA-N N1C=CC2=C(C=NC=C12)C1=NC=2N(C(=C1)N1CCOCC1)N=C(C=2)CN1CCC(CC1)C(C)(C)O Chemical compound N1C=CC2=C(C=NC=C12)C1=NC=2N(C(=C1)N1CCOCC1)N=C(C=2)CN1CCC(CC1)C(C)(C)O SSQIVSBCTXQXDN-UHFFFAOYSA-N 0.000 claims 1
- VZZWCNRZKDWUDI-UHFFFAOYSA-N NC1=NC=C(C=C1)C1=NC=2N(C(=C1)N1CCOCC1)N=C(C=2)CN1CCC(CC1)C(C)(C)O Chemical compound NC1=NC=C(C=C1)C1=NC=2N(C(=C1)N1CCOCC1)N=C(C=2)CN1CCC(CC1)C(C)(C)O VZZWCNRZKDWUDI-UHFFFAOYSA-N 0.000 claims 1
- QGNAPMIBAOEPPA-UHFFFAOYSA-N NC1=NC=C(C=N1)C1=NC=2N(C(=C1)N1CCOCC1)N=C(C=2)CN1CCC(CC1)C(C)(C)O Chemical compound NC1=NC=C(C=N1)C1=NC=2N(C(=C1)N1CCOCC1)N=C(C=2)CN1CCC(CC1)C(C)(C)O QGNAPMIBAOEPPA-UHFFFAOYSA-N 0.000 claims 1
- BWCAQDUWZQVCPE-UHFFFAOYSA-N OC(C)(C)C1CCN(CC1)CC1=NN2C(N=C(C=C2N2CCOCC2)C2=C3C=CNC3=CC=C2)=C1 Chemical compound OC(C)(C)C1CCN(CC1)CC1=NN2C(N=C(C=C2N2CCOCC2)C2=C3C=CNC3=CC=C2)=C1 BWCAQDUWZQVCPE-UHFFFAOYSA-N 0.000 claims 1
- ZNKVXCYSSZJNOF-UHFFFAOYSA-N OC(C)(C)C1CCN(CC1)CC1=NN2C(N=C(C=C2N2CCOCC2)C2=C3C=CNC3=CC=C2)=C1C Chemical compound OC(C)(C)C1CCN(CC1)CC1=NN2C(N=C(C=C2N2CCOCC2)C2=C3C=CNC3=CC=C2)=C1C ZNKVXCYSSZJNOF-UHFFFAOYSA-N 0.000 claims 1
- CJXGJDBDBXMEBD-UHFFFAOYSA-N OC(C)(C)C1CCN(CC1)CC1=NN2C(N=C(C=C2N2CCOCC2)C2=C3C=CNC3=CC=C2F)=C1 Chemical compound OC(C)(C)C1CCN(CC1)CC1=NN2C(N=C(C=C2N2CCOCC2)C2=C3C=CNC3=CC=C2F)=C1 CJXGJDBDBXMEBD-UHFFFAOYSA-N 0.000 claims 1
- GQJWPNOBZBGYFM-UHFFFAOYSA-N OC(C)(C)C1CCN(CC1)CC1=NN2C(N=C(C=C2N2CCOCC2)C2=C3C=NNC3=CC=C2)=C1 Chemical compound OC(C)(C)C1CCN(CC1)CC1=NN2C(N=C(C=C2N2CCOCC2)C2=C3C=NNC3=CC=C2)=C1 GQJWPNOBZBGYFM-UHFFFAOYSA-N 0.000 claims 1
- 125000002393 azetidinyl group Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- XKPGGAABWMLPKO-UHFFFAOYSA-N cyclopropyl-[4-[[5-(1H-indol-4-yl)-7-morpholin-4-ylpyrazolo[1,5-a]pyrimidin-2-yl]methyl]piperazin-1-yl]methanone Chemical compound C1(CC1)C(=O)N1CCN(CC1)CC1=NN2C(N=C(C=C2N2CCOCC2)C2=C3C=CNC3=CC=C2)=C1 XKPGGAABWMLPKO-UHFFFAOYSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- FQIWHPALNIWULM-UHFFFAOYSA-N thiomorpholine-2,3-dione Chemical compound O=C1NCCSC1=O FQIWHPALNIWULM-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (18)
1. Spoj opće formule (I)
naznačen time, da:
Y predstavlja -CH2- ili >C=O;
R1 je odabran iz skupine koja se sastoji od A1, A2 i A3:
R2 predstavlja:
- polovicu dioksotiomorfolina B1;
- polovicu piperazinila B2
pri čemu dva ugljikova atoma piperazinskog prstena mogu po izboru biti spojena s metilenskim mostom -CH2- kako bi se dobila 2,5-diazabiciklička polovica, a R5 je odabran iz skupine koja se sastoji od -SO2CH3; -C(O)-C1-C3-alkila, -C(O)-C3-C5- cikloalkila; fenila supstituiranog s-O-C1-C3 alkilom; i -CR6R7R8,
pri čemu R6, R7 i R8 neovisno predstavljaju vodikov atom, CH3, ciklopropil ili CONH2, pod uvjetom da jedan od R6, R7 i R8 može predstavljati ciklopropil ili CONH2,
ili jedan od R6, R7 i R8 predstavlja vodikov atom a ostala dva od R6, R7 i R8 su spojena zajedno kako bi se dobila -(CH2)2, -(CH2)3, -(CH2)4 ili -(CH2-O-CH2)- skupina;
- polovica azetidinila B3
pri čemu je R9 odabran iz skupine koja se sastoji od morfolina, 2,6- dimetilomorfolina, 1,1-dioksotiomorfolina, 4,4-difluoropiperidinila i 3- metoksiazetidin-1-ila; ili
- polovica piperidinila B4
pri čemu je R10 odabran iz skupine koja se sastoji od C1-C4 alkila; C1-C4 alkila supstituiranog s OH; -COO(C1C3-alkil); -N(C1-C3 alkil); -NHCONH-C1-C3- alkil; -NHCONH-C1-C3-fenil; piperazinil; i piperazinila supstituiranog na položaju 4 s C1-C3 alkilom;
R3 je odabran iz skupine koja se sastoji od H, halogena i C1-C4 alkila;
R4 je odabran iz skupine koja se sastoji od C1-C4 alkila, C3-C4-cikloalkila, C1-C4 alkila supstituiranog s C1-C4 alkoksi i CHF2;
X1 i X2 imaju sljedeće značenje:
(i) X1 predstavlja CH i X2 predstavlja CH ili N;
(ii) X1 predstavlja N i X2 predstavlja CH ili
(iii) X1 predstavlja CH i X2 predstavlja C-O-CH3;
X3, X4, X5 i X6 imaju sljedeće značenje:
(i) X3 predstavlja N, X4 predstavlja CH, X5 predstavlja CH i X6 predstavlja CH;
(ii) X3 predstavlja CH, X4 predstavlja N, X5 predstavlja CH i X6 predstavlja CH;
(iii) X3 predstavlja CH, X4 predstavlja CH, X5 predstavlja N i X6 predstavlja CH;
(iv) X3 predstavlja CH, X4 predstavlja CH, X5 predstavlja CH i X6 predstavlja CH ili CF; ili
(v) X3 predstavlja CH, X4 predstavlja CH, X5 predstavlja CF i X6 predstavlja CH;
X7 predstavlja CH ili N;
valovita crta označava točku spajanja;
i njihova farmaceutski prihvatljiva sol.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da Y predstavlja –CH2-.
3. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da Y predstavlja >C=O.
4. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time, da R3 predstavlja H.
5. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time, da R3 predstavlja C1-C4 alkil.
6. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time, da R3 predstavlja halogen.
7. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time, da R1 predstavlja A1 ili A2.
8. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time, da R1 predstavlja A3.
9. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačen time, da R2 predstavlja B1.
10. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačen time, da R2 predstavlja B2.
11. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačen time, da R2 predstavlja B3.
12. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačen time, da R2 predstavlja B4.
13. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je odabran iz skupine koja se sastoji od
2-((4-(ciklopropankarbonil)piperazin-1-il)metil)-5-(1H-indol-4-il)-7-(morfolin-4- il)pirazolo[1,5-a]pirimidina;
5-(1H-indol-4-il)-2-((4-(metilsulfonil)piperazin-1-il)metil)-7-(morfolin-4-il)- pirazolo[1,5-a]pirimidina;
5-(1 H-indol-4-il)-2-((4-(4-metilpiperazin-1 -il)piperidin-1 -il)metil)-7-(morfolin-4- il)pirazolo[1,5-a]pirimidina;
2-((4-(2-hidroksipropan-2-il)piperidin-1-il)metil)-5-(1H-indol-4-il)-7-(morfolin-4- il)pirazolo[1,5-a]pirimidina;
2-((4-(dimetilamino)piperidin-1-il)metil)-5-(1H-indol-4-il)-7-(morfolin-4-il)- pirazolo[1,5-a]pirimidina;
5-(1H-indol-4-il)-2-((4-(4-metoksifenil)piperazin-1-il)metil)-7-(morfolin-4-il)- pirazolo[1,5-a]pirimidina;
2-((4-(2-hidroksipropan-2-il)piperidin-1-il)metil)-5-(5-fluoro-1H-indol-4-il)-7- (morfolin-4-il)pirazolo[1,5-a]pirimidina;
2-((4-terc-butilpiperazin-1-il)metil)-5-(1H-indol-4-il)-7-(morfolin-4- il)pirazolo[1,5-a]pirimidina;
2-(4-((5-(1H-indol-4-il)-7-(morfolin-4-il)pirazolo[1,5-a]pirimidin-2-il)- metil)piperazin-1-il)-2-metilpropionamida;
2-(4-((5-(5-fluoro-1H-indol-4-il)-7-(morfolin-4-il)pirazolo[1,5-a]pirimidin-2- il)metil)piperazin-1-il)-2-metilpropionamida;
2-((4-terc-butilpiperazin-1-il)metil)-5-(5-fluoro-1H-indol-4-il)-7-(morfolin-4-il)- pirazolo[1,5-a]pirimidina;
2-((4-terc-butilpiperazin-1-il)metil)-5-(1H-indazol-4-il)-7-(morfolin-4-il)- pirazolo[1,5-a]pirimidina;
2-((4-(dimetilamino)piperidin-1-il)metil)-5-(5-fluoro-1H-indol-4-il)-7-(morfolin-4-i l) pirazolo [1,5-a]pirimidina;
5-(5-fluoro-1H-indol-4-il)-2-((4-(4-metilpiperazin-1-il)piperidin-1-il)metil)-7- (morfolin-4-il)pirazolo[1,5-a]pirimidina;
2-((4-(2-hidroksipropan-2-iL)piperidin-1-il)metil)-5-(1H-indazoL-4-il)-7-(morfolin-4-il)pirazolo[1,5-a]pirimidina;
5-(2-aminopiridin-5-il)-2-((4-terc-butilpiperazin4-il)metil)-7-(morfolin-4- il)pirazolo[1,5-a]pirimidina;
5-(2-aminopirimidin-5-il)-2-((4-terc-butilpiperazin-1-il)metil)-7-(morfolin-4-ii) pirazolo[ 1,5-a]pirimidina;
5-(2-aminopirimidin-5-il)-2-((4-(2-hidroksipropan-2-il)piperidin-1-il)metil)-7- (morfolin-4-il)pirazolo[1,5-a]pirimidina;
5-(2-aminopiridin-5-il)-2-((4-(2-hidroksipropan-2-il)piperidin-1-il)metil)-7- (morfolin-4-il)pirazolo[1,5-a]pirimidina;
2-((4-ciklopropilpiperazin-1-il)metil)-5-(1H-indol-4-il)-7-(morfolin-4-il)pi razolo[1,5-a]pirimidina;
5-(1 H-indol-4-il)-2-((4-metilpiperazin4 -il)metil)-7-(morfolin-4-il)pirazolo[1,5-a]- pirimidina;
2-((4-etilpiperazin-1-il)metil)-5-(1H-indol-4-il)-7-(morfolin-4-il)pirazolo[1,5- a]pirimidina;
2-((1,1 -dioksotiomorfolin-1 -il)metil)-5-(1 H-indol-4-il)-7-(morfolin-4-il) pirazolo[1,5-a]pirimidina;
metil 1 -((5-(1 H-indol-4-il)-7-(morfolin-4-il)pirazolo[1,5-a]pirimidin-2-il)metil)- pi peridin -4- karboksilata;
5-(1H-indol-4-il)-2-((3-(morfolin-4-il)azetidin-1-il)metil)-7-(morfolin-4- il)pirazolo[1,5-a]pirimidin;2-((4-(ciklopropilmetil)piperazin-1-il)metil)-5-(1H-indol-4-il)-7-(morfolin-4-il)pirazolo[1,5-a]pirimidina;
2-((4-ciklopentilpiperazin-1-il)metil)-5-(1H-indol-4-il)-7-(morfolin-4-ii) pirazolo [ 1,5-a]pirimidina;
2-((4-terc-butilpiperidin-1-il)metil)-5-(1H-indol-4-il)-7-(morfolin-4- il)pirazolo[1,5-a]pirimidina;
5-(1H-6-azaindol-4-il)-2-((4-(2-hidroksipropan-2-il)piperidin-1-il)metil)-7- (morfolin-4-il)pirazolo[1,5-a]pirimidina;
5-(1H-6-azaindol-4-il)-2-((4-terc-butilpiperazin-1-il)metil)-7-(morfolin-4-il)- pirazolo[1,5-a]pirimidina;
5-(1H-indol-4-il)-2-((3-(1,1-dioksotiomorfolin-4-il)azetidin-1 -il)metil)-7- (morfolin-4-il)pirazolo[1,5-a]pirimidina;
5-(1 H-7-azaindol-4-il)-2-((4-terc-butilpiperazin-1 -il)metil)-7-(morfolin-4-il)- pirazolo[1,5-a]pirimidina;
5-(1H-7-azaindol-4-il)-2-((4-(2-hidroksipropan-2-il)piperidin-1-il)metil)-7- (morfolin-4-il)pirazolo[1,5-a]pirimidina;
5-(1H-indol-4-il)-2-((4-(oksetan-3-il)piperidin-1-il)metil)-7-(morfolin-4-il)- pirazolo[1,5-a]pirimidina;
5-(1H-5-fluoro1ndol-4-il)-2-((4-(oksetan-34l)piperidin-1-1l)metil)-7-(morfolin-4- il)pirazolo[1,5-a]pirimidina;
5-(1H-indol-4-il)-2-(((1S,4S)-2-(oksetan-3-il)-2,5-diazabiciklo[2.2.1]hept-2-il)- metil)-7-(morfolin-4-il)pirazolo[1,5-a]-pirimidina;
3-etil-1-(1-((5-(1H-indol-4-il)-7-(morfolin-4-il)pirazolo[1,5-a]pirimidin-2-il)- metil)piperidin-4-il)uree;
1-fenil-3-(1-((5-(1H-indol-4-il)-7-(morfolin-4-il)pirazolo[1,5-a]pirimidin-2-il)- metil)piperidin-4-il)uree;
2-((4-terc-butilpiperazin-1-il)metil)-5-(5-fluoro-1H-indol-4-il)-7-(morfolin-4- il)pirazolo[1,5-a]pirimidina;
2-((4-terc-butilpiperazin-1-il)metil)-5-(1H-indol-4-il)-3-metil-7-(morfolin-4-il)- pirazolo[1,5-a]pirimidina;
2-((4-(2-hidroksipropan-2-il)piperidin-1-il)metil)-5-(1H-indol-4-il)-3-metil-7- (morfolin-4-il)pirazolo[1,5-a]pirimidina;
5-(2-etilbenzimidazol-1-il)-2-((4-(metilsulfonil)piperazin-1-il)metil)-7-(morfolin-4-il)pirazolo[1,5-a]pirimidina;
5-(2-etilbenzimidazo-1-il)-2-{(4-{dimetilamino)piperidin-1-il)metil)-7-(morfolin-4-il)pirazolo[1,5-a]pirimidina;
5-(2-etilbenzimidazol-1-il)-2-((4-(4-metilpiperazin-1-il)piperidin-1-il)metil)-7- (morfolin-4-il)pirazolo[1,5-a]pirimidina;
5-(2-etilbenzimidazol-1-il)-2-((4-(4-metoksifenil)piperazin-1-il)metil)-7- (morfolin-4-il)pirazolo[1,5-a]pirimidina;
5-(2-etilbenzimidazol-1-il)-2-((4-(2-hidroksipropan-2-il)pipendin-1-il)metil)-7- (morfolin-4-il)pirazolo[1,5-a]pirimidina;
5-(2-etilbenzimidazol-1-il)-2-((4-terc-butilpiperazin-1-il)metil)-7-(morfolin-4- il)pirazolo[1,5-a]pirimidina;
5-(2-metilbenzimidazol-1-il)-2-((4-terc-butilopiperazin-1-il)metil)-7-(morfolin-4- il)pirazolo[1,5-a]pirimidina;
5-(2-metilbenzimidazol-1-il)-2-((4-(2-hidroksipropan-2-il)piperidin-1-il)metil)-7- (morfolin-4-il)pirazolo[1,5-a]pirimidina;
5-(2-(difluorometil)benzimidazol-1-il)-2-((4-terc-butilpiperazin-1-il)metil)-7- (morfolin-4-il)pirazolo[1,5-a]pirimidina;
5-(2-(difluorometil)benzimidazol-1-il)-2-((4-(2-hidroksipropan-2-il)piperidin-1-il)- metil)-7-(morfolin-4-1l)pirazolo[1,5-a]pirimidina;
5-(2-izo-propilbenzimidazol-1-il)-2-((4-terc-butilpiperazin-1-il)metil)-7-(morfolin-4-il)pirazolo[1,5-a]pirimidina;
5-(2-1zo-propilbenzimidazol-1-il)-2-((4-(2-hidroksipropan-2-il)piperidin-1- il)metil)-7-(morfolin-4-il)pirazolo[1,5-a]pirimidina;
5-(2ciklopropilbenzimidazol-1-il)-2-((4-tert-butylpiperazin-1-il)metil)-7- (morfolin-4-il)pirazolo[1,5-a]pirimidina;
5-(2-ciklopropilbenzimidazol-1-il)-2-((4-(2-hidroksipropan-2-il)piperidiril- il)metil)-7-(morfolin-4-il)pirazolo[1,5-a]pirimidina;
542-etilimidazo[4,5-b]piridin-1-il)-2-((4-terc-butilpiperazin-1-il)metil)-7- (morfolin-4-il)pirazolo[1,5-a]pirimidina;
5-(2-etilimidazo[4,5-c]piridin-1-il)-2-((4-terc-butilpiperazin-1-il)metil)-7-(morfolin-4-il)pirazolo[1,5-a]pirimidina;
5-(2-etil-5-metoksibenzimidazol-1-il)-2-((4-terc-butilpiperazin-1-il)metil)-7- (morfolin-4-il)pirazolo[1,5-a]pirimidina;
5-(2-etil-5-metoksibenzimidazol-1-il)-2-((4-(2-hidroksipropan-2-il)piperidin-1-il)- metil)-7-(morfolin-4-il)pirazolo[1,5-a]pirimidina;
5-(2-difluorometil-5-metoksibenzimidazol-1-il)-2-((4-terc-butilpiperazin-1-il)- metil)-7-(morfolin-4-il)pirazolo[1,5-a]pirimidina;
5-(2-difluorometil-5-metoksibenzimidazol-1-il)-2-((4-(2-hidroksipropan-2-il)- piperidin-1-il)metil)-7-(morfolin-4-il)pirazolo[1,5-a]pirimidina;
5-(2-(difluorometil)imidazo[4,5-c]piridin-1-il)-2-((4-terc-butilpiperazin-1- il)metit)-7-(morfolin-4-il)pirazolo[1,5-a]pirimidina;
5-(2-(metoksimetil)-benzimidazol-1-il)-2-((4-terc-butilpiperazin-1-il)metil)-7- (morfolin-4-il)pirazolo[1,5-a]pirimidina;
5-(2-(difluorometil)benzimidazol-1-il)-2-((3-(morfolin-4-il)azetidin-1-il)metil)-7- (morfolin-4-il)pirazolo[1,5-a]pirimidina;
5-(2-(difluorometil)benzimidazol-1-il)-2-((3-((2R,6S)-2,6-dimetilmorfolin-4-il)- azetidin-1-il)metil)-7-(morfolin-4-il)pirazolo[1,5-a]pirimidina;
5-(2-(difluorometil)benzimidazol-1-il)-2-((3-(4,4-difluoropiperidin-1-il)azetidin-1- il)metil)-7-(morfolin-4-il)pirazolo[1,5-a]pirimidina;
5-(2-(difluorometil)benzimidazol-1-il)-2-((3-(3-metoksiazetidin-1-il)azetidin-1- il)metil)-7-(morfolin-4-il)pirazolo[1,5-a]pirimidina;
5-(2-(difluorometil)benzimidazol-1-il)-3-metil-2-((4-terc-butilpiperazin-1-il)- metil)-7-(morfolin-4-il)pirazolo[1,5-a]pirimidina;
5-(2-(difluorometil)benzimidazol-1-il)-3-metil-2-((4-(2-hidroksipropan-2-il)- piperidin-1-il)metil)-7-{morfolin-4-il)pirazolo[1,5-a]pirimidina;
2-(4-terc-butilpiperazin-1-ilkarbonil)-5-(1H-indol-4-il)-7-(morfolin-4- il)pirazolo[1,5-a]pirimidina;
5-(2-(difluorometil)benzimidazol-1-il)-3-kloro-2-((4-terc-butilpiperazin-1- il)metil)-7-(morfolin-4-il)pirazolo[1,5-a]pirimidina; i
5-(2-(difluorometil)benzimidazol-1-il)-3-bromo-2-((4-terc-butilpiperazin-1- il)metil)-7-(morfolin-4-il)pirazolo[1,5-a]pirimidina.
14. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je 5-(2- (difluorometil)benzimidazol-1-il)-2-((4-terc-butilpiperazin-1-il)metil)-7- (morfolin-4-il)pirazolo[1,5-a]pirimidin.
15. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je 5-(1H-6- azaindol-4-il)-2-((4-terc-butilpiperazin-1-il)metil)-7-(morfolin-4-il)- pirazolo[1,5-a]pirimidin.
16. Spoj formule (I) kako je definiran u bilo kojem od patentnih zahtjeva 1 do 15, naznačen time, da se koristi kao lijek.
17. Spoj formule (I) kako je definiran u bilo kojem od patentnih zahtjeva 1 do 15, naznačen time, da se koristi u postupku liječenja bolesti imunološkog sustava, upalnih oboljenja te karcinoma.
18. Farmaceutski pripravak, naznačen time, da sadrži spoj formule (I) kako je definiran u bilo kojem od patentnih zahtjeva 1 do 15 i farmaceutski prihvatljive ekscipijense.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL411864A PL236355B1 (pl) | 2015-04-02 | 2015-04-02 | Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3 |
PCT/IB2016/051792 WO2016157091A1 (en) | 2015-04-02 | 2016-03-30 | 7-(morpholin-4-yl)pyrazole[1,5-a]pyrimidine derivatives which are useful for the treatment of immune or inflammatory diseases or cancer |
EP16714019.3A EP3277687B1 (en) | 2015-04-02 | 2016-03-30 | 7-(morpholin-4-yl)pyrazole[1,5-a]pyrimidine derivatives which are useful for the treatment of immune or inflammatory diseases or cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20192195T1 true HRP20192195T1 (hr) | 2020-03-06 |
Family
ID=55650626
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20192195TT HRP20192195T1 (hr) | 2015-04-02 | 2019-12-06 | Derivati 7-(morfolin-4-il)pirazol[1,5-a]pirimidina koji su korisni za liječenje imunoloških ili upalnih oboljenja ili karcinoma |
Country Status (18)
Country | Link |
---|---|
US (1) | US10138247B2 (hr) |
EP (1) | EP3277687B1 (hr) |
JP (1) | JP6665201B2 (hr) |
KR (1) | KR102559190B1 (hr) |
CN (1) | CN107743489B (hr) |
AU (1) | AU2016241568B2 (hr) |
BR (1) | BR112017020131B1 (hr) |
CA (1) | CA2978828A1 (hr) |
DK (1) | DK3277687T3 (hr) |
EA (1) | EA032826B1 (hr) |
ES (1) | ES2765642T3 (hr) |
HR (1) | HRP20192195T1 (hr) |
HU (1) | HUE047822T2 (hr) |
MX (1) | MX2017011423A (hr) |
PL (2) | PL236355B1 (hr) |
PT (1) | PT3277687T (hr) |
SI (1) | SI3277687T1 (hr) |
WO (1) | WO2016157091A1 (hr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2023542724A (ja) | 2020-09-28 | 2023-10-11 | ファースト・バイオセラピューティクス・インコーポレイテッド | 造血前駆細胞キナーゼ1(hpk1)阻害剤としてのインダゾールおよびその使用方法 |
CN114957261B (zh) * | 2022-05-17 | 2023-06-23 | 重庆文理学院 | 一种具有抗头颈癌作用的化合物及其制备方法和应用 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0880523B1 (en) * | 1996-02-07 | 2006-08-16 | Neurocrine Biosciences, Inc. | Pyrazolopyrimidines as crf receptor antagonists |
CA2550729A1 (en) | 2003-12-23 | 2005-07-14 | Activbiotics, Inc. | Rifamycin analogs and uses thereof |
KR100968291B1 (ko) * | 2005-02-11 | 2010-07-07 | 에프. 호프만-라 로슈 아게 | Mglur2 길항제로서의 피라졸로-피리미딘 유도체 |
PL2094709T3 (pl) * | 2006-09-20 | 2011-02-28 | Lilly Co Eli | Tiazolopirazolopirymidyny jako antagoniści receptora crf1 |
CA2703138A1 (en) | 2007-10-26 | 2009-04-30 | F. Hoffmann-La Roche Ag | Purine derivatives useful as pi3 kinase inhibitors |
EP2257552A1 (en) | 2008-02-26 | 2010-12-08 | Novartis AG | Heterocyclic compounds as inhibitors of cxcr2 |
EP2279188B1 (en) * | 2008-05-30 | 2015-01-28 | Genentech, Inc. | Purine pi3k inhibitor compounds and methods of use |
AU2009299894A1 (en) * | 2008-10-03 | 2010-04-08 | Merck Serono S.A. | 4 -morpholino-pyrido [3, 2 -d] pyrimidines active on Pi3k |
JP5578490B2 (ja) * | 2008-12-26 | 2014-08-27 | 味の素株式会社 | ピラゾロピリミジン化合物 |
AU2010238361B2 (en) * | 2009-04-16 | 2015-08-06 | Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii | Imidazopyrazines for use as kinase inhibitors |
WO2010136491A1 (en) | 2009-05-27 | 2010-12-02 | F. Hoffmann-La Roche Ag | Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use |
JP5781066B2 (ja) | 2009-05-27 | 2015-09-16 | ジェネンテック, インコーポレイテッド | p110δに対して選択的な二環式ピリミジンPI3K阻害剤化合物及び使用方法 |
GB0912745D0 (en) | 2009-07-22 | 2009-08-26 | Wolfson Microelectronics Plc | Improvements relating to DC-DC converters |
BR112012019635A2 (pt) | 2010-02-22 | 2016-05-03 | Hoffmann La Roche | compostos inibidores de pirido[3,2-d] pirimidina pi3k delta e métodos de uso |
AU2011223888B2 (en) | 2010-03-04 | 2015-07-02 | Merck Sharp & Dohme Llc | Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders |
US9096605B2 (en) * | 2011-08-24 | 2015-08-04 | Glaxosmithkline Llc | Pyrazolopyrimidine derivatives as PI3 kinase inhibitors |
-
2015
- 2015-04-02 PL PL411864A patent/PL236355B1/pl unknown
-
2016
- 2016-03-30 DK DK16714019.3T patent/DK3277687T3/da active
- 2016-03-30 KR KR1020177031214A patent/KR102559190B1/ko active IP Right Grant
- 2016-03-30 WO PCT/IB2016/051792 patent/WO2016157091A1/en active Application Filing
- 2016-03-30 ES ES16714019T patent/ES2765642T3/es active Active
- 2016-03-30 SI SI201630560T patent/SI3277687T1/sl unknown
- 2016-03-30 MX MX2017011423A patent/MX2017011423A/es active IP Right Grant
- 2016-03-30 PL PL16714019T patent/PL3277687T3/pl unknown
- 2016-03-30 BR BR112017020131-3A patent/BR112017020131B1/pt active IP Right Grant
- 2016-03-30 EA EA201792087A patent/EA032826B1/ru not_active IP Right Cessation
- 2016-03-30 HU HUE16714019A patent/HUE047822T2/hu unknown
- 2016-03-30 CN CN201680017259.4A patent/CN107743489B/zh active Active
- 2016-03-30 EP EP16714019.3A patent/EP3277687B1/en active Active
- 2016-03-30 CA CA2978828A patent/CA2978828A1/en active Pending
- 2016-03-30 PT PT167140193T patent/PT3277687T/pt unknown
- 2016-03-30 US US15/562,537 patent/US10138247B2/en active Active
- 2016-03-30 JP JP2017551627A patent/JP6665201B2/ja active Active
- 2016-03-30 AU AU2016241568A patent/AU2016241568B2/en active Active
-
2019
- 2019-12-06 HR HRP20192195TT patent/HRP20192195T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
MX2017011423A (es) | 2018-05-17 |
EA032826B1 (ru) | 2019-07-31 |
DK3277687T3 (da) | 2019-12-16 |
CN107743489A (zh) | 2018-02-27 |
JP2018510192A (ja) | 2018-04-12 |
KR102559190B1 (ko) | 2023-07-25 |
EA201792087A1 (ru) | 2018-03-30 |
PL411864A1 (pl) | 2016-10-10 |
BR112017020131A2 (pt) | 2018-05-29 |
PL3277687T3 (pl) | 2020-09-21 |
PT3277687T (pt) | 2020-01-10 |
EP3277687A1 (en) | 2018-02-07 |
WO2016157091A1 (en) | 2016-10-06 |
US10138247B2 (en) | 2018-11-27 |
EP3277687B1 (en) | 2019-10-30 |
BR112017020131B1 (pt) | 2023-02-28 |
AU2016241568B2 (en) | 2019-09-26 |
CN107743489B (zh) | 2021-05-04 |
CA2978828A1 (en) | 2016-10-06 |
ES2765642T3 (es) | 2020-06-10 |
SI3277687T1 (sl) | 2020-02-28 |
KR20170132275A (ko) | 2017-12-01 |
JP6665201B2 (ja) | 2020-03-13 |
PL236355B1 (pl) | 2021-01-11 |
US20180111939A1 (en) | 2018-04-26 |
AU2016241568A1 (en) | 2017-10-19 |
HUE047822T2 (hu) | 2020-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2018138471A (ru) | Гетероциклические соединения в качестве ингибиторов киназы RET | |
JP2019535664A5 (hr) | ||
HRP20191268T1 (hr) | Derivati tieno[2,3-c]pirol-4-ona kao inhibitori erk | |
NZ766835A (en) | Pharmaceutical compounds | |
RU2019115115A (ru) | Производные пиперидина в качестве ингибиторов убиквитин-специфической протеазы 7 | |
HRP20170712T1 (hr) | Novi spojevi selektivnih antagonista nk-3 receptora, farmaceutski pripravak i postupci za uporabu kod poremećaja uzrokovanih nk-3 receptorima | |
RU2014151004A (ru) | Пирролопиримидоновые и пирролопиридоновые ингибиторы танкиразы | |
JP2019515903A5 (hr) | ||
AR107127A1 (es) | Indazoles sustituidos, procedimientos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos | |
HRP20151398T1 (hr) | Tricikliäśni derivati amina kao inhibitori protein tirozin kinaze | |
NZ598907A (en) | Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors | |
PH12016501164A1 (en) | Heteroaryl substituted nicotinamide compounds | |
HRP20192151T1 (hr) | Derivati izokromena kao inhibitori fosfoinozitid 3-kinaza | |
JP2015508075A5 (hr) | ||
SI3083625T1 (en) | Pyrimidopyrimidinones, useful as Wee-1 kinase inhibitors | |
IL257587A (en) | Compounds for the treatment of lateral amyotrophic sclerosis | |
RU2016151315A (ru) | Некоторые ингибиторы протеинкиназы | |
WO2005079807A1 (en) | Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists | |
RU2015149937A (ru) | Соединения для модулирования киназы и показания к их применению | |
RU2016111675A (ru) | Соединения биарилацетамида и способы их применения | |
JP2011511034A5 (hr) | ||
NZ628186A (en) | Compounds for treating spinal muscular atrophy | |
RU2012148133A (ru) | Комбинация, включающая ингибитор циклинзависимой киназы 4 или циклинзависимой киназы 6 (cdk4/6) и ингибитор mtor, для лечения рака | |
RU2015148189A (ru) | ПРОИЗВОДНЫЕ 2-АМИДОПИРИДО[4, 3-d]ПИРИМИДИН-5-ОНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ WEE-1 | |
TW200800213A (en) | Novel imidazo based heterocycles |